6-(4-methoxyphenyl)-2-(4-phenyl-5-sulfanylidene-1H-1,2,4-triazol-3-yl)-4,5-dihydropyridazin-3-one | 1273319-46-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 6-(4-methoxyphenyl)-2-(4-phenyl-5-sulfanylidene-1H-1,2,4-triazol-3-yl)-4,5-dihydropyridazin-3-one
• CAS: 1273319-46-2
• 化学式: C₁₉H₁₇N₅O₂S
• 分子量: 379.442
• InChiKey: CWOPXZSPCSSBCP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  102
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  3-(4-甲氧基苯甲酰基)丙酸 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 4.0h， 生成 6-(4-methoxyphenyl)-2-(4-phenyl-5-sulfanylidene-1H-1,2,4-triazol-3-yl)-4,5-dihydropyridazin-3-one
  参考文献：
  名称：

  Triazole incorporated pyridazinones as a new class of antihypertensive agents: Design, synthesis and in vivo screening

  摘要：

  A number of 6-(substituted phenyl)-2-(4-substituted phenyl-5-thioxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)-4,5-dihydropyridazin-3(2H)-one derivatives were designed and synthesized by a sequence of reactions starting from respective aryl hydrocarbons. The final compounds (4a-4u) were evaluated for antihypertensive activities by non-invasive method using Tail Cuff method. The compounds 4e, 4i and 4k showed appreciable antihypertensive activity comparable with that of standard hydralazine and propranolol. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.12.028

文献信息

• Triazole incorporated pyridazinones as a new class of antihypertensive agents: Design, synthesis and in vivo screening
  作者：Anees A. Siddiqui、Ravinesh Mishra、Mohammad Shaharyar、Asif Husain、Mohd. Rashid、Palash Pal

  DOI：10.1016/j.bmcl.2010.12.028

  日期：2011.2

  A number of 6-(substituted phenyl)-2-(4-substituted phenyl-5-thioxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)-4,5-dihydropyridazin-3(2H)-one derivatives were designed and synthesized by a sequence of reactions starting from respective aryl hydrocarbons. The final compounds (4a-4u) were evaluated for antihypertensive activities by non-invasive method using Tail Cuff method. The compounds 4e, 4i and 4k showed appreciable antihypertensive activity comparable with that of standard hydralazine and propranolol. (C) 2010 Elsevier Ltd. All rights reserved.